Osteonecrosis of the Jaw Involving Bisphosphonate Treatment for Osteoporosis

M, Panas; Zaleska, Małgorzata; Kaczmarzyk, Tomasz

doi:10.5772/31089

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recurrence rate of MRONJ is high, however, it can be reduced with proper procedures [52][53][54][55]. According to an analysis made in eight Japanese units in the years 2006-2016, in 361 patients that were observed for approximately 15 months each, a complete recovery was obtained in 25.2% of patients that underwent conservative treatment.…”

Section: Treatmentmentioning

confidence: 99%

Medication-Related Osteonecrosis of the Jaw—A Continuing Issue

Wróbel¹,

Sikora

Chęciński³

et al. 2021

Applied Sciences

View full text Add to dashboard Cite

Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a condition that is becoming more common in the everyday practice of both dental and maxillofacial surgeons. Materials and methods: This paper aims to provide a comprehensive and easy to read by clinicians presentation of comprehensive, accessible, and up-to-date data on MRONJ. The individual chapters focus on the etiology, epidemiology, diagnosis, prevention, treatment, and recurrence of MRONJ. Results and discussion: It has been observed over the years that among drugs that increase the risk of the disease, apart from bisphosphonates, angiogenesis inhibitors and anti-RANKL monoclonal antibodies should also be included. A thorough physical and subjective examination, periodic correction of dental prostheses, and an adequate preparation for even the simplest of procedures in the oral cavity area can prevent or minimize the risk of MRONJ. Conclusions: It is extremely difficult to treat once it occurs and oftentimes is a recurring problem that leads to a multitude of symptoms that gradually decrease the quality of a patient’s life.

show abstract

Section: Treatmentmentioning

confidence: 99%